Literature DB >> 26448668

Lenvatinib and Palbociclib.

Dominic A Solimando, J Aubrey Waddell.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2015        PMID： 26448668      PMCID： PMC4589862          DOI： 10.1310/hpj5007-578

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  17 in total

1.  Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.

Authors:  J W Harbour; R X Luo; A Dei Santi; A A Postigo; D C Dean
Journal:  Cell       Date:  1999-09-17       Impact factor: 41.582

2.  Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Authors:  John P Leonard; Ann S LaCasce; Mitchell R Smith; Ariela Noy; Lucian R Chirieac; Scott J Rodig; Jian Q Yu; Shankar Vallabhajosula; Heiko Schoder; Patricia English; Donna S Neuberg; Peter Martin; Michael M Millenson; Scott A Ely; Rachel Courtney; Naveed Shaik; Keith D Wilner; Sophia Randolph; Annick D Van den Abbeele; Selina Y Chen-Kiang; Jeffrey T Yap; Geoffrey I Shapiro
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

3.  Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.

Authors:  Keith T Flaherty; Patricia M Lorusso; Angela Demichele; Vandana G Abramson; Rachel Courtney; Sophia S Randolph; M Naveed Shaik; Keith D Wilner; Peter J O'Dwyer; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2011-11-16       Impact factor: 12.531

4.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

5.  E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.

Authors:  Kenji Ikuta; Seiji Yano; Van The Trung; Masaki Hanibuchi; Hisatsugu Goto; Qi Li; Wei Wang; Tadaaki Yamada; Hirokazu Ogino; Soji Kakiuchi; Hisanori Uehara; Yoshitaka Sekido; Toshimitsu Uenaka; Yasuhiko Nishioka; Saburo Sone
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

6.  Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.

Authors:  Robert Shumaker; Jagadeesh Aluri; Jean Fan; Gresel Martinez; Min Ren; Kun Chen
Journal:  Int J Clin Pharmacol Ther       Date:  2014-04       Impact factor: 1.366

7.  E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.

Authors:  Junji Matsui; Yuji Yamamoto; Yasuhiro Funahashi; Akihiko Tsuruoka; Tatsuo Watanabe; Toshiaki Wakabayashi; Toshimitsu Uenaka; Makoto Asada
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

8.  A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.

Authors:  D S Boss; H Glen; J H Beijnen; M Keesen; R Morrison; B Tait; W Copalu; A Mazur; J Wanders; J P O'Brien; J H M Schellens; T R J Evans
Journal:  Br J Cancer       Date:  2012-04-19       Impact factor: 7.640

9.  Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.

Authors:  Noriyuki Koyama; Kenichi Saito; Yuki Nishioka; Wataru Yusa; Noboru Yamamoto; Yasuhide Yamada; Hiroshi Nokihara; Fumiaki Koizumi; Kazuto Nishio; Tomohide Tamura
Journal:  BMC Cancer       Date:  2014-07-21       Impact factor: 4.430

10.  A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

Authors:  Ana M Molina; Thomas E Hutson; James Larkin; Anne M Gold; Karen Wood; Dave Carter; Robert Motzer; M Dror Michaelson
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-05       Impact factor: 3.333
View more
  1 in total

1.  Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways.

Authors:  Daye Zhang; Yongxiang Zhang; Zeyuan Cai; Ying Tu; Zhansong Hu
Journal:  Exp Ther Med       Date:  2019-11-21       Impact factor: 2.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.